Patents Assigned to GlaxoSmithKline
-
Publication number: 20240083896Abstract: Compounds of formula (I) are described, wherein each of the variable groups is as defined in the specification. Also described are pharmaceutical compositions containing a compound of formula (I), and uses of the compounds and pharmaceutical compositions for inhibiting Nav1.8 voltage-gated sodium channels and treating Nav1.8 mediated diseases, disorders, and conditions, such as pain and pain-associated diseases, disorders, and conditions and cardiovascular diseases, disorders, and conditions, such as atrial fibrillation.Type: ApplicationFiled: December 16, 2021Publication date: March 14, 2024Applicant: GlaxoSmithKline Intellectual Property Development LimitedInventors: Xiaoyang DONG, Mark Andrew ELBAN, Jie GUANG, Ming-Hsun HO, Tram H. HOANG, Joseph J. ROMANO, David Glenn WASHBURN
-
Publication number: 20240051972Abstract: The invention relates to compounds of Formula (I), (Ia), (Ib), (II) or (III), salts thereof, pharmaceutical compositions thereof, as well as therapeutic methods of treatment and prevention.Type: ApplicationFiled: August 31, 2022Publication date: February 15, 2024Applicants: GlaxoSmithKline Intellectual Property Development Limited, The University of North Carolina at Chapel Hill, ViiV Healthcare CompanyInventors: Martha DE LA ROSA, Richard M. DUNHAM, David MARGOLIS, Vincent Wing-Fai TAI, Jun TANG
-
Publication number: 20240025988Abstract: Provided herein are interleukin 7 (IL-7) binding proteins, pharmaceutical compositions and their use in the treatment or prevention of a disease or condition.Type: ApplicationFiled: September 5, 2023Publication date: January 25, 2024Applicant: GlaxoSmithKline Intellectual Property Development LimitedInventors: Gerben BOUMA, Edward Thomas COULSTOCK, David DIXON, Stephanie HOPLEY, Alan Peter LEWIS, Jessica Lynn NEISEN
-
Patent number: 11873310Abstract: The invention relates to compounds of Formula (I), (Ia), (Ib), (II) or (III), salts thereof, pharmaceutical compositions thereof, as well as therapeutic methods of treatment and prevention.Type: GrantFiled: August 6, 2021Date of Patent: January 16, 2024Assignee: GlaxoSmithKline Intellectual Property Development LimitedInventors: Vincent Wing-Fai Tai, Jun Tang
-
Publication number: 20240009307Abstract: Disclosed herein is a method of treating cancer, such as multiple myeloma, involving the combination of an anti-BCMA antigen binding protein (e.g., an anti-BCMA antibody) and an immunomodulatory drug (e.g. pomalidomide or lenalidomide). The combinations can also include an anti-inflammatory compound (e.g. dexamethasone).Type: ApplicationFiled: August 22, 2023Publication date: January 11, 2024Applicant: GlaxoSmithKline Intellectual Property Developement LimitedInventors: Sanjay KHANDEKAR, Patrick MAYES, Joanna OPALINSKA
-
Patent number: 11865080Abstract: RNA encoding an immunogen is co-delivered to non-immune cells as the site of delivery and also to immune cells which infiltrate the site of delivery. The responses of these two cell types to the same delivered RNA lead to two different effects, which interact to produce a strong immune response against the immunogen. The non-immune cells translate the RNA and express the immunogen. Infiltrating immune cells respond to the RNA by expressing type I interferons and pro-inflammatory cytokines which produce a local adjuvant effect which acts on the immunogen-expressing non-immune cells to upregulate major histocompatibility complex expression, thereby increasing presentation of the translated protein to T cells. The effects on the immune and non-immune cells can be achieved by a single delivery of a single RNA e.g., by a single injection.Type: GrantFiled: December 13, 2022Date of Patent: January 9, 2024Assignee: GlaxoSmithKline Biologicals SAInventors: Andrew Geall, Katrin Ramsauer, Gillis Otten, Christian Walter Mandl
-
Patent number: 11857562Abstract: RNA encoding an immunogen is co-delivered to non-immune cells as the site of delivery and also to immune cells which infiltrate the site of delivery. The responses of these two cell types to the same delivered RNA lead to two different effects, which interact to produce a strong immune response against the immunogen. The non-immune cells translate the RNA and express the immunogen. Infiltrating immune cells respond to the RNA by expressing type I interferons and pro-inflammatory cytokines which produce a local adjuvant effect which acts on the immunogen-expressing non-immune cells to upregulate major histocompatibility complex expression, thereby increasing presentation of the translated protein to T cells. The effects on the immune and non-immune cells can be achieved by a single delivery of a single RNA e.g., by a single injection.Type: GrantFiled: December 13, 2022Date of Patent: January 2, 2024Assignee: GlaxoSmithKline Biologicals SAInventors: Andrew Geall, Katrin Ramsauer, Gillis Otten, Christian Walter Mandl
-
Patent number: 11819544Abstract: The present invention discloses modified Staphylococcus aureus ClfA proteins that contain glycosylation site consensus sequences. The invention also discloses a conjugate comprising a modified ClfA protein and an antigen (for example a Staphylococcus aureus saccharide antigen), wherein the antigen is linked (either directly or through a linker) to an amino acid residue of the modified ClfA protein.Type: GrantFiled: December 19, 2018Date of Patent: November 21, 2023Assignee: GlaxoSmithKline Biologicals SAInventors: Amirreza Faridmoayer, Sabina Marietta Gerber, Stefan Jochen Kemmler
-
Publication number: 20230364219Abstract: Compounds useful as components of immunogenic compositions for the induction of an immunogenic response in a subject against infection, methods for their use in treatment, and processes for their manufacture are provided herein. The compounds comprise a nucleic acid construct comprising a sequence which encodes an antigen, in particular a Coronavirus antigen.Type: ApplicationFiled: April 16, 2021Publication date: November 16, 2023Applicant: GlaxoSmithKline Biologicals SAInventors: Dong YU, Giulietta MARUGGI, Jason W. WESTERBECK, Jeffrey B. ULMER, Jason P. LALIBERTE, Kate LUISI, Lin QU
-
Publication number: 20230346902Abstract: A composition comprising Shigella-Tetravalent (4-valent Shigella) bioconjugates. That encompasses the Shigella O-polysaccharide antigens of serotypes Shigella flexneri 2a, 3a, 6 and Shigella sonnei covalently linked to the protein carrier.Type: ApplicationFiled: June 17, 2021Publication date: November 2, 2023Applicant: GlaxoSmithKline Biologicals SAInventors: Martin Edward BRAUN, Rainer FOLLADOR, Stefan Jochen KEMMLER
-
Patent number: 11795474Abstract: The invention relates to retroviral producer cell comprising nucleic acid sequences encoding: gag and pol proteins; envelope protein or a functional substitute thereof; amplifiable selection marker; and the RNA genome of the retroviral vector particle, wherein said nucleic acid sequences are all integrated at a single locus within the retroviral producer cell genome. The invention also relates to nucleic acid vectors comprising a non-mammalian origin of replication and the ability to hold at least 25 kilobases (kb) of DNA, characterized in that said nucleic acid vector comprises retroviral nucleic acid sequences encoding: gag and pol proteins, and an env protein or a functional substitute thereof. The nucleic acid vector additionally comprises nucleic acid sequences encoding an amplifiable selection marker. The invention also relates to uses and methods using said nucleic acid vector in order to produce stable retroviral packaging and producer cell lines.Type: GrantFiled: April 18, 2018Date of Patent: October 24, 2023Assignee: GlaxoSmithKline Intellectual Property Development LimitedInventor: Conrad Vink
-
Patent number: 11773139Abstract: The invention provides Epstein-Barr Virus antigen polynucleotides, polypeptides and vectors; as well as immunogenic compositions comprising the same. It includes the use of Epstein-Barr Virus antigen constructs to produce vaccines for treating and preventing Epstein-Barr Virus infections and Epstein-Barr Virus-associated diseases, such as multiple sclerosis, rheumatoid arthritis and systemic lupus erythematosus.Type: GrantFiled: December 14, 2018Date of Patent: October 3, 2023Assignee: GlaxoSmithKline Biologicals SAInventors: Stefania Capone, Antonella Folgori, Armin Lahm, Benjamin Wizel
-
Patent number: 11773078Abstract: This invention relates to novel compounds according to Formula (I) which are inhibitors of furin, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the treatment of fibrotic diseases, including pulmonary fibrosis, renal fibrosis, liver fibrosis, skin fibrosis, ocular fibrosis, cardiac fibrosis, and other miscellaneous fibrotic conditions. The disclosed compounds may also be useful for treating other furin-mediated conditions, including but not limited to, hypertension, cancer, infectious diseases, and genetic disorders (e.g., cystic fibrosis (CF)), and neurodegenerative disorders.Type: GrantFiled: May 10, 2019Date of Patent: October 3, 2023Assignee: Glaxosmithkline Intellectual Property Development LimitedInventors: Jeffrey Michael Axten, Mui Cheung, Michael P. Demartino, Huiping Amy Guan, Yan Hu, Aaron Bayne Miller, Donghui Qin, Chengde Wu, Zhiliu Zhang, Xiaojuan Lin
-
Patent number: 11766401Abstract: RNA encoding an immunogen is delivered in a liposome for the purposes of immunisation. The liposome includes lipids which have a pKa in the range of 5.0 to 7.6 and, preferably, a tertiary amine. These liposomes can have essentially neutral surface charge at physiological pH and are effective for immunisation.Type: GrantFiled: December 22, 2021Date of Patent: September 26, 2023Assignee: GlaxoSmithKline Biologicals SAInventor: Andrew Geall
-
Patent number: 11759475Abstract: RNA encoding an immunogen is co-delivered to non-immune cells as the site of delivery and also to immune cells which infiltrate the site of delivery. The responses of these two cell types to the same delivered RNA lead to two different effects, which interact to produce a strong immune response against the immunogen. The non-immune cells translate the RNA and express the immunogen. Infiltrating immune cells respond to the RNA by expressing type I interferons and pro-inflammatory cytokines which produce a local adjuvant effect which acts on the immunogen-expressing non-immune cells to upregulate major histocompatibility complex expression, thereby increasing presentation of the translated protein to T cells. The effects on the immune and non-immune cells can be achieved by a single delivery of a single RNA e.g., by a single injection.Type: GrantFiled: December 13, 2022Date of Patent: September 19, 2023Assignee: GlaxoSmithKline Biologicals SAInventors: Andrew Geall, Katrin Ramsauer, Gillis Otten, Christian Walter Mandl
-
Patent number: 11744890Abstract: Crude aqueous extracts of Quillaja saponaria Molina containing at least the QS-21 main peak and 2018 component, wherein the ratio of 2018 component/QS-21 main peak is ?0.075, as measured by UV absorbance at 214 nm, methods for obtaining such extracts and related aspects.Type: GrantFiled: November 30, 2018Date of Patent: September 5, 2023Assignee: GlaxoSmithKline Biologicals SAInventors: Ahmad Taimour Baig, Juan Jose Diaz Garcia, Chad Austin Farrenburg, Kent Raymond Myers, Jeri Kay Sandvick, Jeb Yeatts Vandenburg
-
Patent number: 11730754Abstract: RNA encoding an immunogen is co-delivered to non-immune cells as the site of delivery and also to immune cells which infiltrate the site of delivery. The responses of these two cell types to the same delivered RNA lead to two different effects, which interact to produce a strong immune response against the immunogen. The non-immune cells translate the RNA and express the immunogen. Infiltrating immune cells respond to the RNA by expressing type I interferons and pro-inflammatory cytokines which produce a local adjuvant effect which acts on the immunogen-expressing non-immune cells to upregulate major histocompatibility complex expression, thereby increasing presentation of the translated protein to T cells. The effects on the immune and non-immune cells can be achieved by a single delivery of a single RNA e.g., by a single injection.Type: GrantFiled: December 13, 2022Date of Patent: August 22, 2023Assignee: GlaxoSmithKline Biologicals SAInventors: Andrew Geall, Katrin Ramsauer, Gillis Otten, Christian Walter Mandl
-
Patent number: 11717529Abstract: RNA encoding an immunogen is co-delivered to non-immune cells as the site of delivery and also to immune cells which infiltrate the site of delivery. The responses of these two cell types to the same delivered RNA lead to two different effects, which interact to produce a strong immune response against the immunogen. The non-immune cells translate the RNA and express the immunogen. Infiltrating immune cells respond to the RNA by expressing type I interferons and pro-inflammatory cytokines which produce a local adjuvant effect which acts on the immunogen-expressing non-immune cells to upregulate major histocompatibility complex expression, thereby increasing presentation of the translated protein to T cells. The effects on the immune and non-immune cells can be achieved by a single delivery of a single RNA e.g., by a single injection.Type: GrantFiled: December 13, 2022Date of Patent: August 8, 2023Assignee: GlaxoSmithKline Biologicals SAInventors: Andrew Geall, Katrin Ramsauer, Gillis Otten, Christian Walter Mandl
-
Patent number: 11708394Abstract: The present invention provides mutated fHbp polypeptides and fusion proteins comprising said mutated fHbp polypeptides that are useful as components of immunogenic compositions for immunizing against Neisseria meningitidis infection.Type: GrantFiled: August 9, 2019Date of Patent: July 25, 2023Assignee: GlaxoSmithKline Biologicals SAInventors: Maria Scarselli, Daniele Veggi
-
Patent number: 11707482Abstract: RNA encoding an immunogen is co-delivered to non-immune cells as the site of delivery and also to immune cells which infiltrate the site of delivery. The responses of these two cell types to the same delivered RNA lead to two different effects, which interact to produce a strong immune response against the immunogen. The non-immune cells translate the RNA and express the immunogen. Infiltrating immune cells respond to the RNA by expressing type I interferons and pro-inflammatory cytokines which produce a local adjuvant effect which acts on the immunogen-expressing non-immune cells to upregulate major histocompatibility complex expression, thereby increasing presentation of the translated protein to T cells. The effects on the immune and non-immune cells can be achieved by a single delivery of a single RNA e.g., by a single injection.Type: GrantFiled: December 13, 2022Date of Patent: July 25, 2023Assignee: GlaxoSmithKline Biologicals SAInventors: Andrew Geall, Katrin Ramsauer, Gillis Otten, Christian Walter Mandl